Navigation Links
ev3 Inc. Reports Third Quarter 2008 Financial Results
Date:10/31/2008

7,083 6,429

Other long-term liabilities 5,381 3,037

Total liabilities 87,173 128,625

Stockholders' equity

Common stock, $0.01 par value;

300,000,000 shares authorized;

shares

issued and outstanding:

105,896,421 shares at September

28, 2008 and

105,078,769 shares at December 31,

2007 1,059 1,051

Additional paid in capital 1,753,572 1,739,064

Accumulated deficit (825,541) (781,039)

Accumulated other comprehensive loss (480) (595)

Total stockholders' equity 928,610 958,481

Total liabilities and stockholders'

equity $1,015,783 $1,087,106

ev3 Inc.

SELECTED NET SALES INFORMATION

(Dollars in thousands, except per share amounts)

(unaudited)

For the Three For the Nine

NET SALES BY SEGMENT Months Ended Months Ended

September September September September

28, 30, % 28, 30, %

2008 2007 change 2008 2007 change

Peripheral vascular

Atherectomy $20,992 $- NA $68,624 $- NA

Stents 26,772 23,105 16% 77,932 65,064 20%

Thrombectomy

and embolic

protection 6,938 5,368 29% 19,990 20,029 0%

Procedural

support and

other 12,184 10,240 19% 35,243 30,742 15%

Total'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. eResearchTechnology Reports Third Quarter 2008 Results
2. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VANCOUVER , Dec. 22, 2014 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development of ... paper out of the University of Calgary in conjunction ... North Carolina, which further validates the company,s ongoing clinical ... the effects of pattern baldness. The paper ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Oct. 23 Celator Pharmaceuticals today,announced that Scott Jackson, ... Investor Forum in San Francisco. Mr. Jackson will,provide a ... programs. The presentation will be held on Wednesday, October,29, ... of the Palace Hotel., The company is also ...
... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will hold a conference call to discuss,the ... update,including an update on the ongoing development activities ... McMahon, Ph.D., chairman and chief executive officer, Ronald ...
... recognizes excellence in ChIP, DNA methylation innovation ... Genpathway, Inc. announced today,that the company has ... American,Services in Drug Discovery Technologies Healthcare Innovation ... providing superior services for,chromatin immunoprecipitation (ChIP) and ...
Cached Biology Technology:Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum 2Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30 2Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award 2Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award 3
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... New discoveries by researchers at the University ... a first-ever pharmacological treatment for cocaine addiction. ... to treat people with hypertension and anxiety, has ... from retrieving memories associated with cocaine use in ...
... , STONY BROOK, NY"Trophic Downgrading of Planet Earth," a review ... the journal Science, concludes that the decline of ... is causing substantial changes to Earth,s terrestrial, freshwater, and marine ... from ecosystems "may be humankind,s most pervasive influence on nature." ...
... achieved a pivotal breakthrough in the development of a cable ... possible. Armchair quantum wire (AQW) will be a weave ... over long distances. It will be an ideal replacement for ... 5 percent per 100 miles of transmission, said Rice chemist ...
Cached Biology News:UWM research offers hope for treatment of cocaine addiction 2Loss of top animal predators has massive ecological effects 2Loss of top animal predators has massive ecological effects 3'Amplified' nanotubes may power the future 2'Amplified' nanotubes may power the future 3
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP) ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently-tagged progesterone ...
... vectors combine the proven features of the ... and provides all of the benefits and ... vector backbone. The pTriEx vectors have been ... genes in all three expression systems. In ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
Biology Products: